Vinblastine

From ToxBankWiki

Vinblastine
Jump to: navigation, search

Vinblastine
Vinblastine.png
Identifiers
Leadscope Id LS-1859
CAS 865-21-4
DrugBank APRD00708
ChemSpider 211446
UNII 5V9KLZ54CY
Pathway DBs
KEGG D08675
Assay DBs
PubChem CID 241903
ChEMBL 607706
Omics DBs
Properties
ToxCast Accepted no
Toxic Effect Apoptosis
ToxBank Accepted no
Target tubulin


Executive Summary

Summary Information

The table listed below contains a summarized listing of toxic effect information leveraged from the 6th European Framework Programme project LIINTOP. For a complete listing of the Gold Compound evaluation criteria please see the Gold Compound Evaluation and Comments immediately following the summary table below.

SMILES O=C(OC)[C@]4(c2c(c1ccccc1n2)CCN3C[C@](O)(CC)C[C@H](C3)C4)c5c(OC)cc6c(c5)[C@@]89[C@@H](N6C)[C@@](O)(C(=O)OC)[C@H](OC(=O)C)[C@@]7(/C=C\CN([C@@H]78)CC9)CC
InChI

InChI=1S/C46H58N4O9/c1-8-42(54)23-28-24-45(40(52)57-6,36-30(15-19-49(25-28)26-42)29-13-10-11-14-33(29)47-36)32-21-31-34(22-35(32)56-5)48(4)38-44(31)17-20-50-18-12-16-43(9-2,37(44)50)39(59-27(3)51)46(38,55)41(53)58-7/h10-14,16,21-22,28,37-39,47,54-55H,8-9,15,17-20,23-26H2,1-7H3/t28-,37+,38-,39-,42+,43-,44-,45+,46+/m1/s1

InChI-Key

JXLYSJRDGCGARV-XQKSVPLYSA-N

Supplier Sigma Aldrich
Summary Hepatotoxic Effects from the LIINTOP FP6 Program
Hepatocellular necrosis.gif Apoptosis.gif Transporter inhibition.gif Cholestatic.gif Steatotic.gif Phospholipidosis.gif Hepatocyte function.gif Mithochondria impairment.gif Oxidative stress.gif DNA synthesis genotoxicity.gif Covalent binding.gif Idiosyncrasia metabolic.gif Idiosyncrasia immune.gif Bioactivation required.gif LIINTOP severity.gif References
+ +

[1] [2] [3] [4] [5] [6] [7] [8] [9] [10]

Gold Compound Evaluation and Comments

The following table is organized into four main sections and provides a detailed assessment by the Gold Compound Working Group for the use of this compound as a standard hepatotoxin. The table's four sections (collapsed by default but will expand when the "show" link is clicked) contains detailed information for the core set of SEURAT compound acceptance criteria.

Standard to Meet Compound Assessment
Criteria Notes
1.
The in vivo therapeutic window is used to estimate an appropriate concentration for in vitro toxicity assays. This in vitro concentration should also be consistent with the exposure implied by pharmacokinetics parameters.
2.
We prefer compounds that require metabolic activation, although standards that are active in themselves will be accepted if they have otherwise valuable properties. We require knowing the active metabolite, and we prefer compounds where the metabolite is stable and can be independently tested in order to verify the mechanism of toxicity as well as of metabolic activation in the test cell line.
3.
Literature data for at least one, but not necessarily all, of the ‘omics datasets is desired. This requirement can be waived in special cases.
4.
The IC50’s for in vitro efficacy and toxicity should be consistent with the therapeutic ratio observed in the clinic. These parameters will be dependent on specific cell type and culture conditions, but differences of more than 30-fold in the in vitro vs. in vivo therapeutic ratios should be considered suspect and carefully justified.
5.
This is not a requirement, but compounds utilized in the EPA testing program can be assumed to have physical properties verified to be suitable for in vitro cellular assays.
6.
Sparing soluble compounds may be assayed for solubility in serum and the percent serum used specified here.
7.
This property will be measured when a sample of compound becomes available.

Proprietary Toxicity Literature Report

Currently Unavailable

FDA and Label Information

The following link will display all of the currently approved FDA drug products on the market. The web page will contain a table listing all current products by their respective Tradenames and primary active ingredients. The list is navigable by simply clicking on the product of interest, which will in turn list all of the NDA's and ANDA's associated with that product. From here users can click on a specific NDA or ANDA and see documents that have been submitted for the product that the FDA has made available via their website. The types of documents include approval history, letters, reviews and labels.
FDA Approved Products

This next url will perform a search in the FDA's system for all labels for products that contain "Vinblastine" as an active ingredient.
FDA Label Search

PubMed references

The following resource link will perform a PubMed query for the terms "Vinblastine" and "liver toxicity".
Vinblastine Search

References

  1. ↑ Feldmann, G., 2006. Liver apoptosis. Gastroenterol. Clin. Biol. 30, 533–545.
  2. ↑ Gomez-Lechon, M.J., O’Connor, E., Castell, J.V., Jover, R., 2002. Sensitive markers used to identify compounds that trigger apoptosis in cultured hepatocytes. Toxicol. Sci. 65, 299–308.
  3. ↑ Gomez-Lechon, M.J., O’Connor, J.E., Lahoz, A., Castell, J.V., Donato, M.T., 2008. Identification of apoptotic drugs: multiparametric evaluation in cultured hepatocytes. Curr. Med. Chem. 15, 2071–2085.
  4. ↑ Gomez-Lechon, M.J., Ponsoda, X., O’Connor, E., Donato, T., Jover, R., Castell, J.V., 2003. Diclofenac induces apoptosis in hepatocytes. Toxicol. in Vitro 17, 675– 680.
  5. ↑ Kass, G.E., Macanas-Pirard, P., Lee, P.C., Hinton, R.H., 2003. The role of apoptosis in acetaminophen-induced injury. Ann. NY Acad. Sci. 1010, 557–559.
  6. ↑ Ioannides, C., Lewis, D.F., 2004. Cytochromes P450 in the bioactivation of chemicals. Curr. Top. Med. Chem. 4, 1767–1788.
  7. ↑ Kang, P., Dalvie, D., Smith, E., Zhou, S., Deese, A., Nieman, J.A., 2008. Bioactivation of flutamide metabolites by human liver microsomes. Drug Metab. Dispos. 36, 1425–1437.
  8. ↑ Li, A.P., 2002. A review of the common properties of drugs with idiosyncratic hepatotoxicity and the ‘‘multiple determinant hypothesis” for the manifestation of idiosyncratic drug toxicity. Chem. Biol. Interact. 142, 7–23.
  9. ↑ Park, K., Williams, D.P., Naisbitt, D.J., Kitteringham, N.R., Pirmohamed, M., 2005b. Investigation of toxic metabolites during drug development. Toxicol. Appl. Pharmacol. 207, 425–434.
  10. ↑ Reddy, M.V., Storer, R.D., Laws, G.M., Armstrong, M.J., Barnum, J.E., Gara, J.P., McKnight, C.G., Skopek, T.R., Sina, J.F., DeLuca, J.G., Galloway, S.M., 2002. Genotoxicity of naturally occurring indolecompounds: correlation between covalentDNAbinding and other genotoxicity tests. Environ. Mol. Mutagen. 40, 1–17.

Calculated/Predicted Properties

Water Solubility Results
pH Sol,mg/ml Flags  % Graph
2 1000 B 100 Vinblastine solubility.png
5.5 32.01 B 100
6.5 2.16 BN 95/5
7.4 0.35 BN 68/32
10 0.12 N 97
Summary Solubility Data
Intrinsic Solubility,mg/ml 0.1162
Intrinsic Solubility,log(S,mol/l) -3.8439
Solubility in Pure Water at pH = 8.93,mg/ml 0.1214
Calculations performed using ACD/PhysChem v 9.14
Single-valued Properties
Property Value Units Error
Molar Refractivity 220.74 cm3 0.4
Molar Volume 590.05 cm3 5
Parachor 1712.66 cm3 6
Index of Refraction 1.67 3.33E-2
Surface Tension 70.98 dyne/cm 5
Density 1.37 g/cm3 0.1
Polarizability 87.51 10E-24 cm3 0.5
Calculations performed using ACD/PhysChem v 9.14
Property Name Value Units Source
pKa - SPARC v4.5
Estimated VP 1.43E-27 mm Hg EPI Suite v4.10
Estimated VP 1.91E-25 Pa EPI Suite v4.10
Estimated Water Solubility 0.04458 mg/L EPI Suite v4.10
WATERNT Frag Water Solubility Estimate 0.044735 mg/L EPI Suite v4.10
pKa Results
Acidic/Basic Acidic/Basic Aparrent pKa Value Error
14 A 16.7 0.6
48 A 14.61 0.4
33 MA 11.36 0.6
23 MB 7.9 0.6
17 B 5.62 0.7
7 B 1.23 0.7
14 B -3.11 0.6
A = Acidic
B = Basic
MA = Most Acidic
MB = Most Basic
Calculations performed using ACD/PhysChem v 9.14

Authors of this ToxBank wiki page

David Bower, Egon Willighagen, Matthew Clark
Retrieved from "http://wiki.toxbank.net/wiki/Vinblastine"
Facts about VinblastineRDF feed
Accepted by ToxBankno  +
Accepted by ToxCastno  +
Equivalent URIThis property is a special property in this wiki.http://bio2rdf.org/drugbank_drugs:APRD00708  +, http://bio2rdf.org/cas:865-21-4  +, http://www.chemspider.com/Chemical-Structure.211446.rdf  +, http://bio2rdf.org/pubchem:241903  +, http://bio2rdf.org/dr:D08675  +, and http://rdf.openmolecules.net/?InChI=1S/C46H58N4O9/c1-8-42(54)23-28-24-45(40(52)57-6,36-30(15-19-49(25-28)26-42)29-13-10-11-14-33(29)47-36)32-21-31-34(22-35(32)56-5)48(4)38-44(31)17-20-50-18-12-16-43(9-2,37(44)50)39(59-27(3)51)46(38,55)41(53)58-7/h10-14,16,21-22,28,37-39,47,54-55H,8-9,15,17-20,23-26H2,1-7H3/t28-,37+,38-,39-,42+,43-,44-,45+,46+/m1/s1  +
Has CAS865-21-4  +
Has ChEMBL Id607706  +
Has ChemSpider Id211446  +
Has DrugBank IdAPRD00708  +
Has InChIwarning.pngString representation InChI=1S/C46H58N4O9/c1-8-42(54)23-28-24-45 <span class="smwwarning">[…]</span> t28-,37+,38-,39-,42+,43-,44-,45+,46+/m1/s1 is too long.
Has InChIKeyJXLYSJRDGCGARV-XQKSVPLYSA-N  +
Has KEGG IdD08675  +
Has Leadscope IdLS-1859  +
Has PubChem CID241903  +
Has SmilesO=C(OC)[C@]4(c2c(c1ccccc1n2)CCN3C[C@](O)(CC)C[C@H](C3)C4)c5c(OC)cc6c(c5)[C@@]89[C@@H](N6C)[C@@](O)(C(=O)OC)[C@H](OC(=O)C)[C@@]7(/C=C\CN([C@@H]78)CC9)CC  +
Has categoryHepatotoxic  +
Has imageVinblastine.png  +
Has targettubulin  +
Has toxic effectApoptosis  +
Personal tools
Namespaces
Variants
Actions
Navigation
Hepatotoxins
Cardiotoxins
Renal Toxins
Special Substances
Undifferentiated Stem Cells
hiPSC Lines
Liver Cell Lines
iPS-derived Cardiomyocytes
Reagents (Growth Factors)
Reagents (Antibodies)
Reagents (Others)
Suppliers (Cells)
Toolbox